Theseus Pharmaceuticals, Inc. on December 22, 2023, entered into an Agreement and Plan of Merger, dated as of December 22, 2023 with Concentra Biosciences, LLC, and Concentra Merger Sub II, Inc. Pursuant to the terms of the Merger Agreement, at the Effective Time, each of Iain Dukes, Carl Gordon, Donald Hayden, Michael Rome, Steven Stein, Kathy Yi and Bradford Dahms resigned from the board of directors of the Company. Following the Merger and pursuant to the terms of the Merger Agreement, at the Effective Time, the directors and officers of Merger Sub immediately prior to the Effective Time became the directors and officers of the Surviving Corporation. The sole director of Merger Sub immediately prior to the Effective Time was Kevin Tang.

The executive officers of Merger Sub immediately prior to the Effective Time were Kevin Tang, serving as Chief Executive Officer, and Michael Hearne, serving as Chief Financial Officer, Ryan Cole, serving as Chief Operating Officer, Stew Kroll, serving as Chief Development Officer, and Thomas Wei, serving as Chief Business Officer.